GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tsubota Laboratory Inc (TSE:4890) » Definitions » EBIT

Tsubota Laboratory (TSE:4890) EBIT : 円-635.4 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Tsubota Laboratory EBIT?

Tsubota Laboratory's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was 円-546.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was 円-635.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tsubota Laboratory's annualized ROC % for the quarter that ended in Dec. 2023 was -354.88%. Tsubota Laboratory's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3,513.64%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Tsubota Laboratory's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -8.66%.


Tsubota Laboratory EBIT Historical Data

The historical data trend for Tsubota Laboratory's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tsubota Laboratory EBIT Chart

Tsubota Laboratory Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
4.39 257.14 203.37 145.00 -635.37

Tsubota Laboratory Quarterly Data
Mar20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -146.30 -171.35 -231.93 -546.80 314.71

Competitive Comparison of Tsubota Laboratory's EBIT

For the Medical Devices subindustry, Tsubota Laboratory's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tsubota Laboratory's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tsubota Laboratory's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tsubota Laboratory's EV-to-EBIT falls into.



Tsubota Laboratory EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-635.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tsubota Laboratory  (TSE:4890) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tsubota Laboratory's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-2194.136 * ( 1 - -21.01% )/( (633.682 + 862.668)/ 2 )
=-2655.1239736/748.175
=-354.88 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2311.483 - 64.534 - ( 1643.233 - max(0, 496.671 - 2109.938+1643.233))
=633.682

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2002.197 - 65.805 - ( 1509.047 - max(0, 850.582 - 1924.306+1509.047))
=862.668

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Tsubota Laboratory's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2187.188/( ( (66.266 + max(-5.4859999999998, 0)) + (58.231 + max(-410.843, 0)) )/ 2 )
=-2187.188/( ( 66.266 + 58.231 )/ 2 )
=-2187.188/62.2485
=-3,513.64 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.831 + 371.21 + 94.664) - (64.534 + 0 + 407.657)
=-5.4859999999998

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.837 + 292.2 + 122.222) - (65.805 + 0 + 760.297)
=-410.843

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tsubota Laboratory's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-635.366/7339.090
=-8.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tsubota Laboratory EBIT Related Terms

Thank you for viewing the detailed overview of Tsubota Laboratory's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Tsubota Laboratory (TSE:4890) Business Description

Traded in Other Exchanges
N/A
Address
34 Shinanomachi, 304 Toshin Shinanomachi-ekimae Building, Shinjuku-ku, Tokyo, JPN, 160-0016
Tsubota Laboratory Inc is engaged in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia.

Tsubota Laboratory (TSE:4890) Headlines

No Headlines